Novel p53-Mdm2 antogonists that conform to Formula I or to Formula II:
where the prescribed substituent groups are defined, are useful in treating or preventing cancer. In particular, the compounds and their pharmaceutical compositions are useful for treating relapsed/refractory acute myeloid and lymphoid leukemia and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas.
符合公式I或公式II的新型p53-Mdm2
拮抗剂,其中所规定的取代基团,可用于治疗或预防癌症。特别地,这些化合物及其药物组合物对于治疗复发/难治性急性髓系和淋巴系白血病以及难治性慢性淋巴细胞白血病/小细胞淋巴瘤非常有用。